Sarissa Capital Management LP Biocryst Pharmaceuticals Inc Transaction History

Sarissa Capital Management LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $460,481 - $720,385	94,168 Added 9.42%	1,094,168 $5.56 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $1.12 Million - $1.52 Million	225,000 Added 29.03%	1,000,000 $5.99 Million
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $1.63 Million - $2.43 Million	-205,288 Reduced 20.94%	775,000 $6.46 Million
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $4.31 Million - $5.83 Million	-410,502 Reduced 29.52%	980,288 $11.3 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $30.6 Million - $52.3 Million	-2,648,810 Reduced 65.57%	1,390,790 $22.6 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $1.26 Million - $1.75 Million	112,900 Added 2.88%	4,039,600 $55.9 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $4.75 Million - $5.9 Million	-334,300 Reduced 7.85%	3,926,700 $56.4 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $32.1 Million - $58.2 Million	-3,376,700 Reduced 44.21%	4,261,000 $67.4 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $3.96 Million - $7.31 Million	-537,300 Reduced 6.57%	7,637,700 $77.7 Million
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $11.2 Million - $28.5 Million	3,314,000 Added 68.18%	8,175,000 $60.9 Million
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $13 Million - $20.9 Million	3,786,000 Added 352.19%	4,861,000 $16.7 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $2.04 Million - $6.03 Million	1,075,000 New	1,075,000 $5.12 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Sarissa Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Sarissa Capital Management LP with notifications on news.